Global Weight Loss & Diabetes Medicines Portfolio

Market Opportunity GLP-1 receptor agonists and dual agonists (semaglutide & tirzepatide) are among the fastest-growing pharmaceutical segments globally, with sales in tens of billions of USD. In India, demand is surging due to rising diabetes and obesity rates. The market offers excellent opportunities with a mix of originator brands (via local partnerships) and high-volume, affordable Indian generics/biosimilars.


1. Tirzepatide (Dual GIP + GLP-1 Agonist)

Currently one of the top-selling weight loss & diabetes drugs worldwide

Mounjaro – Product Overview Manufacturer: Eli Lilly (India partnership with Cipla) Active Ingredient: Tirzepatide Dosage Form: Once-weekly subcutaneous injection Indications: Type 2 Diabetes Mellitus & chronic weight management (adults with obesity or overweight with comorbidities) India Launch: March 2025 (vials) | KwikPen introduced later in 2025 Status: Rx Only | Exceptional demand and repeat prescriptions

Available Dosage Strengths

Strength Pack Type Doses per Pack Recommended Use
2.5 mg Single-dose Vial 1 dose Starter dose
5 mg Single-dose Vial / KwikPen 1 or 4 doses Initial maintenance dose
7.5 mg KwikPen 4 doses Dose escalation
10 mg KwikPen 4 doses Standard effective dose
12.5 mg KwikPen 4 doses Higher therapeutic dose
15 mg KwikPen 4 doses Maximum approved dose

Key Trade Advantages
  • Highly patient-friendly KwikPen (pre-filled, multi-dose) for better compliance
  • Strong clinical outcomes in both glycemic control and significant weight reduction
  • Genuine Eli Lilly India packaging with security features and full regulatory compliance
  • Cold chain product with good shelf life

Storage: Refrigerate at 2–8°C. Stable at room temperature (<30°C) for up to 30 days. Long expiry.


2. Semaglutide (GLP-1 Receptor Agonist)

Highest volume & most established molecule in the category

Branded Options Ozempic (Novo Nordisk)

  • Indications: Primarily Type 2 Diabetes (with significant weight loss benefits)
  • Strengths: 0.25 mg, 0.5 mg, 1.0 mg (weekly pens)
  • Pack: Pre-filled pens
  • Widely available and doctor-preferred for diabetes management

Wegovy / Poviztra (Novo Nordisk with Emcure)

  • Indications: Chronic weight management (higher dose focus)
  • Strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (weekly)
  • Pack: Pre-filled pens (typically 4 doses)
  • Strong brand pull in weight management clinics

Indian Generic / Biosimilar Versions (Post-patent – High Volume Opportunity) Over 40 Indian manufacturers have launched versions, offering 50-70% lower cost than originators. Excellent margins and fast turnover.

Leading Manufacturers & Brands:

  • Sun Pharmaceutical Industries
    • Noveltreat (weight loss focus) & Sematrinity (diabetes + weight loss)
    • Injectable pens (0.25 mg to 2.4 mg) + oral tablet options
  • Dr. Reddy’s Laboratories
    • Obeda – 2 mg & 4 mg prefilled disposable pens
  • Zydus Lifesciences
    • Semaglyn, Mashema, Alterme – 15 mg/3 mL multi-dose cartridge pens
  • Other Prominent Players: Alkem (Semasize, Obesema), Natco, Torrent, Glenmark, Eris, Lupin, Mankind, etc.

Common Formats: Weekly pre-filled pens (0.25 mg to 2.4 mg titration) + Oral tablets (Rybelsus-like)

Key Trade Advantages

  • Proven track record and high doctor confidence
  • Multiple price points for different customer segments (Ozempic for diabetes, Wegovy for obesity, generics for volume)
  • High repeat purchase rate

Storage: Refrigerate at 2–8°C. Follow specific pack instructions for room temperature use.


3. Liraglutide (GLP-1 Agonist) – Daily Injectable

Reliable & Affordable Alternative

Key Brand: Lirafit (Glenmark) + Biocon biosimilar

  • Strengths: 0.6 mg, 1.2 mg, 1.8 mg up to 3.0 mg daily
  • Pack: Multi-dose pre-filled pens (3 mL)
  • Indications: Type 2 Diabetes & weight management
  • Significantly cheaper than newer weekly injectables

Why Source from Ametheus Holdings?

  • Curated portfolio covering branded (Mounjaro, Ozempic, Wegovy) and generic options
  • 100% genuine products with complete documentation (Certificates of Analysis, Import/Manufacturing licenses, GST compliance)
  • Competitive wholesale pricing with flexible MOQ
  • Reliable pan-India cold chain logistics and timely delivery
  • Marketing support materials (product sheets, images, doctor communication aids)

We help you build a complete Anti-Obesity & Diabetes Injectable range for maximum profitability.

Next Steps – Contact us today for:

  • Detailed price list & MOQ
  • High-resolution product images & catalogues
  • Side-by-side comparison charts
  • Customized buyer presentations


Contact: Ametheus Holdings Pvt Ltd | Phone: +91-9999999538, +91-9999099538, +91-9999156157
Email: info(at)ametheus(dot)com[email protected] ]